4Bio hopes to mix and match next-gen therapies with $150M fund

4Bio Capital is aiming for early stage, highly innovative companies developing ‘advanced therapies’

4Bio Capital is aiming to invest solely in new modalities and treatment paradigms with its new venture fund, including in start-ups that combine more than one novel approach.

The firm has raised $50 million in the first close of 4Bio Ventures II, for which it has set a $150 million target. It will

Read the full 527 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE